Furthermore, the eight CMML cases harboring NPM1 mutations showed aggressive clinical behavior with higher risk of blast transformation (63%), occurring at a median of 5 months since initial diagnosis, compared to patients with NPM1 wild-type (18%). Here, NPM1 is linked to chronic myelomonocytic leukemia.